Zhuomiao Tech Files IPO Prospectus: Pioneering Digital Respiratory Therapeutics with Dynamic Monitoring and Chrono-Therapy for Asthma

Chronic Respiratory Disease (CRD) refers to a group of conditions represented by asthma, chronic obstructive pulmonary disease (COPD), and others. As one of the four major chronic diseases globally, CRD accounts for 10% of all deaths caused by non-communicable diseases worldwide.

Although asthma is a common chronic disease, severe and refractory asthma poses hazards no less significant than those of major illnesses, characterized by clinical features such as difficulty in control and a high rate of acute exacerbations. Severe and refractory asthma are the leading causes of mortality and disability among asthma patients. One well-known victim was Ms. Teresa Teng. Moderate asthma also warrants sufficient attention, as it may progress to severe asthma.

As a respiratory disease, asthma can only be controlled but not cured, leading to frequent exacerbations in some patients and severely impacting their quality of life. Domestic data show that the average cost per hospitalization for asthma patients exceeds RMB 10,000. For many years, medical experts have been attempting to identify indicators capable of predicting asthma exacerbations in advance, but without success to date.

Although there are currently some monitoring protocols internationally, each has certain limitations. For instance, scoring systems that rely on asthma patients’ self-recall are subject to retrospective bias, are difficult for patients to adhere to on a daily basis, and have limited effectiveness in predicting asthma exacerbations. Consequently, interventions at present can often only be initiated after the onset of symptoms, by which time the disease has already caused harm to the patient.

To address the aforementioned pain points,Beijing Zhuomiao Technology Co., Ltd. (hereinafter referred to as “Zhuomiao Technology”)Shifting perspectives, delving deeply into guidelines, and innovatively proposing“Dynamic Monitoring, Sequential Therapy”New Strategies to Reduce the Risk of Acute Exacerbations of Airway Diseases: Dynamically Generating Phased "Temporal Treatment" Strategies Using Monitoring Data to Maximize Therapeutic Efficacy. Under this premise, we have also established“Optimal Pulmonary Function Plateau”to serve as an objective, quantitative metric for evaluating treatment and long-term management; subsequently, sparse monitoring can be leveraged to help patients consistently maintain optimal disease control.Pre-Incident Managementto reduce the likelihood of acute exacerbations. It not only improves patient adherence to monitoring but also achieves the goal of reducing the rate of acute exacerbations.

Zhuomiao Technology has addressed the pain point in traditional monitoring schemes where collected data cannot be fully utilized to optimize patient treatment. By conducting in-depth analysis of monitoring data to formulate a “temporal therapy” strategy, it has truly developed a digital therapeutic tool for respiratory diseases.

The patient population in the field of airway diseases is substantial. In addition to asthma and chronic obstructive pulmonary disease (COPD) mentioned above, this field also includes interstitial lung diseases, cystic fibrosis, and other conditions. Zhuomiao Technology has chosen to enter the market by focusing on asthma, particularly severe and refractory asthma, primarily for two reasons.

First, the daily functioning and quality of life of patients with severe and refractory asthma are severely impacted by the disease, including loss of work capacity, impaired academic performance, and premature mortality. According to foreign surveys, among working-age patients with severe asthma, 14% experience complete work disability attributable to asthma, while 38% have partial work disability. Timely and appropriate interventions are essential for patients at this stage. Furthermore, these patients have an urgent need to improve their quality of life and demonstrate excellent treatment adherence.

Second, patients with severe and refractory asthma bear a substantial medical burden, with treatment costs 1.7 to 5 times higher than those for patients with ordinary asthma. Meanwhile, medical expenditures for severe asthma account for approximately 60% of the total costs for all asthma patients. This presents an urgent need and holds significant practical implications, both from the patient perspective and in terms of national health insurance and health economic efficiency.

Leveraging the founding team’s nearly decade-long industry experience and technological accumulation in airway diseases, Zhuomiao Technology has proposed"Dynamic Monitoring, Sequential Treatment"New Strategies to Reduce the Rate of Acute Exacerbations, Through“Software + Hardware + Algorithms”an ecosystem portfolio that integrates local and cloud-based solutions for airway diseasesIn-Hospital and Out-of-Hospitalclosed-loop management.

"Dynamic Monitoring"It refers to patients using Zhuomiao Technology’s app to collect data on symptoms, medication, and pulmonary function indicators."Chronotherapy"It draws on current hotspots in the oncology field, leveraging data from dynamic monitoring and core algorithmic analysis to propose optimized dosing strategies aimed at achieving adequate therapeutic efficacy.

Notably, key algorithmic models have been developed in collaboration with the respiratory departments of several renowned Grade A tertiary hospitals in Beijing and Shanghai. By leveraging large volumes of real-world, continuous monitoring data, a cloud-based decision support repository has been established. This system employs algorithmic self-learning to continuously refine “time-series therapy” strategies, gradually forming more precise models for predicting drug benefits and digital models for forecasting the risk of acute disease exacerbations.

Zhuomiao Technology employs a strategy of “dynamic monitoring and sequential therapy” to enable patients to rapidly establish their individual “optimal lung function plateau” under adequate treatment conditions. It provides doctors and patients with digital, visualized, and quantifiable metrics for treatment and long-term management, helping patients achieve “fewer symptoms, better lung function, and lower exacerbation rates.”

Zhuomiao Technology’s innovative proposal of the “Dynamic Monitoring, Sequential Treatment” strategy is inextricably linked to its core founding team, which has been deeply engaged in the field of airway diseases for over a decade.

Founder: Ou Zhou, with over 20 years of experience in marketing and operations within China’s healthcare sector. He has worked for international pharmaceutical giants such as Novartis, Boehringer Ingelheim, and Merck & Co., and later facilitated the entry of Swedish company NIOX’s respiratory products into the Chinese market, growing import volume from zero to over RMB 100 million within five years. With more than a decade of deep engagement in China’s respiratory care field, he possesses substantial industry expertise and extensive professional networks.

Wang Hongyi, Head of Medical Affairs/Marketing,Held senior executive positions at numerous renowned domestic and international enterprises, serving as Head of Marketing and Head of Medical Affairs. Possesses over 20 years of experience in R&D, medical affairs, and marketing within the pharmaceutical and medical device industries. With more than a decade of specialized expertise in the respiratory field, excels at unconventional medical thinking and innovative strategies that integrate current clinical practices to create new market focal points. Played a pivotal role in establishing a novel medical and market positioning for the Swedish NIOX respiratory products tailored to the Chinese market, laying a solid medical foundation for the remarkable commercial success of FeNO testing in China.

Over a decade of collaboration has not only fostered comrade-like trust and synergy between them but also established close ties with key opinion leaders (KOLs) in the field of airway diseases. Zhuomiao Technology has received strong support from domestic respiratory experts since project initiation through the early stages of commercialization, receiving timely feedback and recommendations on conceptual design, practical R&D, and project implementation.

“Except for finance, we have worked in every other department within the company. This allows us to clearly identify issues at each stage and determine how to resolve them and drive development.” It is rare for founding teams to rotate positions within their own companies, a practice that reflects Zhuomiao’s team philosophy. The Zhuomiao team advocates for specialized expertise complemented by versatile skills, emphasizes improving per-capita efficiency, and adheres to the principle of “small but elite” to build high-performing teams.

With such a comprehensive team boasting strong medical expertise, robust scientific and technical capabilities, and powerful market expansion strength, Zhuomiao Technology has not only developed high-quality products and service models but also rapidly achieved hospital coverage in key cities across China in terms of commercialization.

In terms of business model, the Zhuomiao Airway Disease Dynamic Monitoring System covers application scenarios from hospitals to homes, targeting both B-end and C-end markets.

The B-side hospital solution comprises three components: the "Physician Professional App," the "Patient Medical App," and the Zhuomiao Portable Pulmonary Function Device (already approved for market launch). It analyzes dynamic monitoring results and provides optimized intervention plans based on time-series treatment strategies for physician reference and decision-making.

Help patients receive adequate treatment, rapidly improve symptoms, and establish a personalized “optimal lung function plateau” as a digital, visualized target for treatment and long-term management. For patients, having a clear understanding of their condition and management goals enables more effective daily monitoring, improves adherence, and reduces disease exacerbations.

Consumer Patient Platform: Comprising the patient-facing home app and Zhuomiao home devices. Patients conduct sparse monitoring assessments at home to maintain pulmonary function indicators at an optimal plateau, thereby reducing the risk of deterioration and acute exacerbations, and enhancing safety.

Regarding the future evolutionary path of Zhuomiao Technology, Ou Zhou stated that over the next three years, the company will continue to advance clinical research and the iterative development of software and hardware in the fields of asthma and chronic obstructive pulmonary disease (COPD), while expanding its indications to cover all airway diseases, including interstitial lung disease and cystic fibrosis. The company also plans to collaborate with global asthma experts to conduct multi-regional clinical studies on the “dynamic monitoring and sequential treatment” strategy, with the aim of contributing to future updates of clinical guidelines.